Stay updated on Resmetirom in NASH and Fibrosis Clinical Trial

Sign up to get notified when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Resmetirom in NASH and Fibrosis Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study content and blocking access to the MAESTRO-NASH (NCT03900429) study details.
    Difference
    17%
    Check dated 2026-09-19T20:42:59.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    A new reference has been added to Publications: HRQL assessments in a 52-week, double-blind, randomized phase III study of resmetirom (MGL-3196) in NASH with fibrosis (MASH), published in Hepatology 2025. This addition provides context on patient-reported outcomes within the MAESTRO-NASH program.
    Difference
    0.0%
    Check dated 2026-08-29T19:02:02.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    Revision updated from v3.6.4 to v3.6.5, indicating a new deployed version of the page metadata. The change appears to be administrative and does not alter study details or user-facing functionality.
    Difference
    0.0%
    Check dated 2026-08-08T11:07:08.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    A new citation for Schattenberg JM et al. on qFibrosis regression with resmetirom was added to the Publications section, and the previous online-ahead-of-print citation was removed.
    Difference
    0.0%
    Check dated 2026-08-01T08:37:41.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The page shows a new revision label, v3.6.4, indicating a version update of the page. This update does not modify the study details or the publicly displayed endpoints.
    Difference
    0.0%
    Check dated 2026-07-25T04:42:09.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    Steatotic Liver Disease has been added to the glossary, and Fatty Liver Disease has been removed. This reflects a terminology update in how liver conditions are described on the page.
    Difference
    0.0%
    Check dated 2026-07-17T22:18:04.000Z thumbnail image

Stay in the know with updates to Resmetirom in NASH and Fibrosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.